Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - periciazine, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: wheat starch; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - severe anxiety and tension states and the maintenance treatment of the psychotic patient. it is useful in controlling such symptoms as impulsiveness and aggression.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 0.2 g/ml - suspension - excipient ingredients: propylene glycol; glycerol; sucrose; citric acid; purified water; sodium hydroxide - for the treatment of poisoning and drug overdosage by oral ingestion.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - aid to the stereotactic or ultrasonic localising of small lesions of the breast for later surgical excision.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 u - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 500 u - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - periciazine, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; wheat starch; magnesium stearate; colloidal anhydrous silica - severe anxiety and tension states and the maintenance treatment of the psychotic patient. it is useful in controlling such symptoms as impulsiveness and aggression.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - periciazine 10mg;  ;   - tablet - 10 mg - active: periciazine 10mg     excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose wheat starch - in adults with schizophrenia or other psychoses, for the treatment of symptoms or prevention of relapse. in anxiety, psychomotor agitation, violent or dangerously impulsive behaviour. neulactil is used as an adjunct to the short-term management of these conditions.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - periciazine 2.5mg;  ;   - tablet - 2.5 mg - active: periciazine 2.5mg     excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose wheat starch - in adults with schizophrenia or other psychoses, for the treatment of symptoms or prevention of relapse. in anxiety, psychomotor agitation, violent or dangerously impulsive behaviour. neulactil is used as an adjunct to the short-term management of these conditions.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - fluorouracil, quantity: 0.5 g; salicylic acid, quantity: 10 g - solution - excipient ingredients: butyl methacrylate/methyl methacrylate copolymer (3:1); ethyl acetate; dimethyl sulfoxide; ethanol absolute; pyroxylin - actikerall is indicated for the topical treatment of solar (actinic) keratosis